Crocodile Capital Partners GmbH Sells 12,163 Shares of BioNTech SE Sponsored ADR $BNTX

Key Points

• Crocodile Capital Partners cut its BioNTech holdings by 41.1% in the third quarter, selling 12,163 shares and retaining 17,423 shares worth approximately $1.71 million.
• BioNTech’s latest quarterly results fell short of expectations, with a loss of $2.53 per share versus the $2.40 consensus estimate and revenue down 59.5% year over year to $122.31 million.
• Insider selling has been substantial: CEO Ugur Sahin sold 72,000 shares under a Rule 10b5-1 plan, while insiders sold approximately 744,000 shares worth $73.3 million over the past 90 days. Analysts nonetheless maintain a “Moderate Buy” consensus with an average price target of $125.69.

Crocodile Capital Partners GmbH lessened its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 41.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,423 shares of the company's stock after selling 12,163 shares during the period. BioNTech comprises approximately 1.1% of Crocodile Capital Partners GmbH's portfolio, making the stock its 7th biggest position. Crocodile Capital Partners GmbH's holdings in BioNTech were worth $1,713,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Integrated Wealth Concepts LLC purchased a new position in BioNTech in the second quarter valued at about $39,000. Farther Finance Advisors LLC raised its holdings in shares of BioNTech by 31.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 493 shares of the company's stock valued at $48,000 after purchasing an additional 118 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of BioNTech by 1,012.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company's stock valued at $53,000 after purchasing an additional 506 shares during the last quarter. Vestcor Inc acquired a new stake in shares of BioNTech in the 4th quarter valued at $153,000. Finally, Rockefeller Capital Management L.P. boosted its holdings in BioNTech by 328.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company's stock worth $177,000 after purchasing an additional 1,423 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at BioNTech

In related news, CEO Ugur Sahin sold 72,000 shares of the company's stock in a transaction on Monday, October 5th. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the completion of the transaction, the chief executive officer directly owned 108,209 shares in the company, valued at $10,521,161.07. This represents a 39.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 744,000 shares of company stock worth $73,301,215 over the last 90 days. Insiders own 19.20% of the company's stock.

BioNTech Stock Performance

Shares of BNTX opened at $92.06 on Friday. The company has a market capitalization of $23.28 billion, a PE ratio of -11.76 and a beta of 1.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The company's fifty day moving average price is $99.04 and its 200 day moving average price is $95.16.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The business had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company's revenue for the quarter was down 59.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.60) earnings per share. As a group, analysts expect that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have commented on BNTX. Morgan Stanley lowered their target price on shares of BioNTech from $115.00 to $114.00 and set an "overweight" rating on the stock in a research report on Wednesday. Argus initiated coverage on BioNTech in a research report on Thursday. They issued a "hold" rating for the company. Wall Street Zen lowered BioNTech from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. UBS Group reissued a "buy" rating on shares of BioNTech in a report on Wednesday, September 16th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of BioNTech in a research note on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $125.69.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company's research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.